ADVERTISEMENT
Latest Blogs, Articles, and More
Crossing Tumor Types: BRCA Experience Points Way to New Diagnostic Paradigm
BY MAURIE MARKMAN, MD
It is now well recognized that the presence of a molecular abnormality shown to be actionable in one tumor type may be highly clinically relevant in other malignancies.
Fosbretabulin and Avastin Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer
BY DARCY LEWIS
Pretreated patients with recurrent ovarian cancer had a 2.5-month progression-free survival benefit when receiving fosbretabulin plus Avastin compared with Avastin alone; however, hypertension rates doubled.
Study Suggests Lung Cancer Screening Criteria May Not Capture All Smokers Who Need It
BY MARY K. CAFFREY
Eligibility criteria set for coverage of low-dose computed tomography for individuals deemed at high risk for lung cancer may actually exclude many potential lung cancer patients who would benefit from screening, according to a new study.
FDA Approves Jadenu, a Simpler Formulation for Administering Deferasirox
BY CHRISTINA IZZO
The Food and Drug Administration (FDA) has approved Jadenu (deferasirox) for the treatment of chronic iron overload, a condition that can affect patients with myelodysplastic syndromes (MDS), sickle cell disease and thalassemia.
FDA Approves Zytiga Label Update for Use in Chemo-Naive Men with Metastatic Prostate Cancer
BY SILAS INMAN
The FDA has updated the label for Zytiga plus prednisone to include data that detailed a significant prolongation in overall survival for Zytiga versus placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer.
Special Feature
ADVERTISEMENT
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$